Navigation Links
Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure
Date:5/3/2011

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Researchers from the University of Cincinnati presented results from a prospective study at the American Roentgen Ray Society 2011 Annual Meeting today, demonstrating how PEM-guided biopsy may expedite pre-operative work-up and reduce radiation exposure for breast cancer patients.  

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment.  Naviscan's Stereo Navigator® Accessory is the first ever commercialized PET-guided biopsy tool and has been FDA-cleared since 2008.

"PEM is useful for performing local staging in women with newly diagnosed breast cancer," stated Dr. Amy Argus, Assistant Professor of Radiology and one of the lead investigators of the study. "When additional breast abnormalities are identified by PEM, accurate PEM-guided biopsy can be performed on the same day as the diagnostic imaging, which decreases the patient's radiation dose and may expedite their preoperative work-up."

In this study, 18 women with breast cancer classified as BIRADS 5 identified on mammography or ultrasound underwent a PEM scan and same day PEM-guided biopsy on 24 index and satellite lesions.  Lesion size was 4-60 mm with a mean size of 16 mm.  Results were concordant for 83% of lesions and discordant for the remaining due to patient movement and operator experience.  PEM is the only technology where physicians are able to biopsy on the same injection of the radiotracer.  This is because the radiotracer utilized, FDG, does not washout of the tumor as with other blood flow-dependant modalities like MRI or BSGI.  By avoiding a double injection of radiotracer, the radiation exposure to the patient and medical personnel is reduced.  Same day procedures are also feasible with PEM given the ease of interpretation compared to other advanced imaging modalities.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
2. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
3. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
4. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
5. Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
6. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. New Study Finds Individuals Who Adhere to Their Diabetes Medication Have a 31% Associated Lower Risk of Hospitalization
9. For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
10. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
11. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):